PortalPublikationenPersonalized therapy in multiple myeloma according to patien...

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

Standard

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). / Palumbo, Antonio; Bringhen, Sara; Ludwig, Heinz; Dimopoulos, Meletios A; Bladé, Joan; Mateos, Maria V; Rosiñol, Laura; Boccadoro, Mario; Cavo, Michele; Lokhorst, Henk; Zweegman, Sonja; Terpos, Evangelos; Davies, Faith; Driessen, Christoph; Gimsing, Peter; Gramatzki, Martin; Hàjek, Roman; Johnsen, Hans E; Fernando, Leal Da Costa; Sezer, Orhan; Spencer, Andrew; Beksac, Meral; Morgan, Gareth; Einsele, Hermann; Miguel, San; Jesus, F; Sonneveld, Pieter.

in: BLOOD, Jahrgang 118, Nr. 17, 17, 2011, S. 4519-4529.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Palumbo, A, Bringhen, S, Ludwig, H, Dimopoulos, MA, Bladé, J, Mateos, MV, Rosiñol, L, Boccadoro, M, Cavo, M, Lokhorst, H, Zweegman, S, Terpos, E, Davies, F, Driessen, C, Gimsing, P, Gramatzki, M, Hàjek, R, Johnsen, HE, Fernando, LDC, Sezer, O, Spencer, A, Beksac, M, Morgan, G, Einsele, H, Miguel, S, Jesus, F & Sonneveld, P 2011, 'Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).', BLOOD, Jg. 118, Nr. 17, 17, S. 4519-4529. <http://www.ncbi.nlm.nih.gov/pubmed/21841166?dopt=Citation>

APA

Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., Rosiñol, L., Boccadoro, M., Cavo, M., Lokhorst, H., Zweegman, S., Terpos, E., Davies, F., Driessen, C., Gimsing, P., Gramatzki, M., Hàjek, R., Johnsen, H. E., Fernando, L. D. C., ... Sonneveld, P. (2011). Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). BLOOD, 118(17), 4519-4529. [17]. http://www.ncbi.nlm.nih.gov/pubmed/21841166?dopt=Citation

Vancouver

Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). BLOOD. 2011;118(17):4519-4529. 17.

Bibtex

@article{9e9c17abd7be47529339a65c4ef2d0aa,
title = "Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).",
abstract = "Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time because of an aging population. Most elderly patients with MM are ineligible for autologous transplantation, and the standard treatment has, until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has improved outcomes; however, elderly patients with MM are more susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-intensity regimens improve the safety profile and thus optimize treatment outcome. Further research into the best treatment strategies for vulnerable elderly patients is urgently needed. Appropriate screening for vulnerability and an assessment of cardiac, pulmonary, renal, hepatic, and neurologic functions, as well as age > 75 years, at the start of therapy allows treatment strategies to be individualized and drug doses to be tailored to improve tolerability and optimize efficacy. Similarly, occurrence of serious nonhematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes.",
keywords = "Humans, Aged, Aged, 80 and over, Europe, Age Factors, Age of Onset, *Frail Elderly, Community Networks, Individualized Medicine/*methods, Multiple Myeloma/epidemiology/*therapy, Vulnerable Populations/statistics & numerical data, Humans, Aged, Aged, 80 and over, Europe, Age Factors, Age of Onset, *Frail Elderly, Community Networks, Individualized Medicine/*methods, Multiple Myeloma/epidemiology/*therapy, Vulnerable Populations/statistics & numerical data",
author = "Antonio Palumbo and Sara Bringhen and Heinz Ludwig and Dimopoulos, {Meletios A} and Joan Blad{\'e} and Mateos, {Maria V} and Laura Rosi{\~n}ol and Mario Boccadoro and Michele Cavo and Henk Lokhorst and Sonja Zweegman and Evangelos Terpos and Faith Davies and Christoph Driessen and Peter Gimsing and Martin Gramatzki and Roman H{\`a}jek and Johnsen, {Hans E} and Fernando, {Leal Da Costa} and Orhan Sezer and Andrew Spencer and Meral Beksac and Gareth Morgan and Hermann Einsele and San Miguel and F Jesus and Pieter Sonneveld",
year = "2011",
language = "English",
volume = "118",
pages = "4519--4529",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",

}

RIS

TY - JOUR

T1 - Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

AU - Palumbo, Antonio

AU - Bringhen, Sara

AU - Ludwig, Heinz

AU - Dimopoulos, Meletios A

AU - Bladé, Joan

AU - Mateos, Maria V

AU - Rosiñol, Laura

AU - Boccadoro, Mario

AU - Cavo, Michele

AU - Lokhorst, Henk

AU - Zweegman, Sonja

AU - Terpos, Evangelos

AU - Davies, Faith

AU - Driessen, Christoph

AU - Gimsing, Peter

AU - Gramatzki, Martin

AU - Hàjek, Roman

AU - Johnsen, Hans E

AU - Fernando, Leal Da Costa

AU - Sezer, Orhan

AU - Spencer, Andrew

AU - Beksac, Meral

AU - Morgan, Gareth

AU - Einsele, Hermann

AU - Miguel, San

AU - Jesus, F

AU - Sonneveld, Pieter

PY - 2011

Y1 - 2011

N2 - Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time because of an aging population. Most elderly patients with MM are ineligible for autologous transplantation, and the standard treatment has, until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has improved outcomes; however, elderly patients with MM are more susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-intensity regimens improve the safety profile and thus optimize treatment outcome. Further research into the best treatment strategies for vulnerable elderly patients is urgently needed. Appropriate screening for vulnerability and an assessment of cardiac, pulmonary, renal, hepatic, and neurologic functions, as well as age > 75 years, at the start of therapy allows treatment strategies to be individualized and drug doses to be tailored to improve tolerability and optimize efficacy. Similarly, occurrence of serious nonhematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes.

AB - Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time because of an aging population. Most elderly patients with MM are ineligible for autologous transplantation, and the standard treatment has, until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has improved outcomes; however, elderly patients with MM are more susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-intensity regimens improve the safety profile and thus optimize treatment outcome. Further research into the best treatment strategies for vulnerable elderly patients is urgently needed. Appropriate screening for vulnerability and an assessment of cardiac, pulmonary, renal, hepatic, and neurologic functions, as well as age > 75 years, at the start of therapy allows treatment strategies to be individualized and drug doses to be tailored to improve tolerability and optimize efficacy. Similarly, occurrence of serious nonhematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes.

KW - Humans

KW - Aged

KW - Aged, 80 and over

KW - Europe

KW - Age Factors

KW - Age of Onset

KW - Frail Elderly

KW - Community Networks

KW - Individualized Medicine/methods

KW - Multiple Myeloma/epidemiology/therapy

KW - Vulnerable Populations/statistics & numerical data

KW - Humans

KW - Aged

KW - Aged, 80 and over

KW - Europe

KW - Age Factors

KW - Age of Onset

KW - Frail Elderly

KW - Community Networks

KW - Individualized Medicine/methods

KW - Multiple Myeloma/epidemiology/therapy

KW - Vulnerable Populations/statistics & numerical data

M3 - SCORING: Journal article

VL - 118

SP - 4519

EP - 4529

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 17

M1 - 17

ER -